Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “THROMBOPLASTIN”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,315 records · Page 73Linked to original sources
PubMed1990

Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.

Five different APTT-reagents, two amidolytic anti-IIa assays, one amidolytic anti-Xa assay, and one coagulometric anti-Xa/anti-IIa assay were used to assess the effect of heparin in patients treated for venous thromboembolic disease. Good correlations were observed between log-transformed APTTs determined with the various reagents (correlation coefficients: 0.92-0.96). Nevertheless there were important differences in the slopes of the lines of relationship between the APTT reagents. Good correlations were observed between the anti-Xa and anti-IIa assay results (correlation coefficients: 0.92-0.97). However, the amidolytic anti-Xa activity was significantly higher (p less than 0.001) than the two amidolytic anti-IIa activities. Less good correlations were observed between the log-transformed APTTs and the anti-Xa or anti-IIa activities (correlation coefficients: 0.64-0.78). The correlations were improved by transforming the APTT into APTT-ratio, i.e. the ratio of the patient's APTT to the same patient's APTT after removal of heparin from the plasma sample by means of ECTEOLA-cellulose treatment. The correlation coefficients of log (APTT-ratio) with anti-Xa or anti-IIa ranged from 0.76 to 0.87. For both APTT and amidolytic heparin assay, the response to in vitro heparin was different from the response to ex vivo heparin. Therefore, equivalent therapeutic ranges should be assessed by using ex vivo samples rather than in vitro heparin. Because of the response differences between the APTT reagents, it is not adequate to define a therapeutic range for heparin therapy without specification of the reagent.

Administration, Oral↗
PubMed1989

[Procoagulant properties of the amniotic fluid. IV. The acceleration time of thromboplastin in the amniotic fluid in pathologic pregnancy].

With the purpose of know the behaviour of the thromboplastic acceleration time in amniotic fluid, there were analized 390 amniotic fluids, 241 from normal pregnancies and 149 from abnormal pregnancies, of these, 52 from diabetic women, and 97 from hypertensive women. It was found an important increase in T.A.T. with the progress of pregnancy and their usefulness as fetal lung maturity test. It was concluded, that this method is easy, cheap, and highly specific, so it can be the first election test for determination of fetal lung maturity in low resources Obstetric Centers.

Amniotic Fluid↗
PubMed1977

Rapid loss of factor XII and XI activity in ellagic acid-activated normal plasma: role of plasma inhibitors and implications for automated activated partial thromboplastin time recording.

Rapid prolongation of the aPTT of normal plasma upon incubation with ellagic acid containing aPTT reagents was observed. The aPTT prolongation was not due to time-dependent changes in pH in the incubation mixture or loss of activity of the labile coagulation factors VIII and V but occurred as a result of rapid progressive inactivation of ellagic acid-activated factors XII and XI. Prolongation of the aPTT and loss of contact factor activities was not observed in plasma incubated with particulate activator reagents. This finding seemed to indicate that adsorption of factors XII and XI to larger particles during the activation process might protect these factors from inactivation by naturally occurring plasma inhibitors. Evidence is presented which supports previous findings that C1-INH, alpha1-AT, and antithrombin (in the presence of heparin) contribute to factor XIIa and XI a inactivation in ellagic acid-activated plasma and that plasma albumin may compete with factor XII for ellagic acid binding. The data indicate that ellagic acid-containing aPTT reagents have unfavorable properties which seriously limit their usefulness in the clinical laboratory, particularly in respect to recording of the aPTT with certain fully automated clot timers.

Antithrombins↗
PubMedDate not supplied

[Induction of thromboplastin-like procoagulating activity by Mycoplasma pneumonia].

The capacity of a strain of Mycoplasma pneumoniae to induce the production of procoagulant activity by human mononuclear cells is described. This finding could contribute to the understanding of the pathogenetic mechanism(s) involved in the thromboembolic complications often associated with fatal cases of Mycoplasma pneumoniae infection.

Blood Coagulation↗